INTRODUCTION
With the benefit of significant modifications over the past decade, Gleason grading still provides important information for guiding prostate cancer patients' management and prognostication. In 2005 [1] and more recently in 2014 [2 && ], the International Society of Urological Pathology (ISUP) held two consensus conferences to update prostate cancer grading. As a result of both consensus conferences few important changes in the grading of prostate cancer have occurred. Despite the recent updates, the ISUP-modified Gleason grading system still has few significant limitations. Although the original Gleason system ranged from 2 to 10, the lowest score currently assigned to a prostate tumor on needle biopsy is 6, contributing to the patients' discomfort to consider active surveillance for a lesion with apparent intermediate aggressive potential. Until recently, different studies have improperly grouped together various scores, particularly 3 þ 4 ¼ 7 and 4 þ 3 ¼ 7 erroneously assuming a similar prognosis.
In 2013, Epstein and colleagues [3] at Johns Hopkins University proposed five prognostic risk categories. Unlike Gleason scores, the Grade Groups use a scale of 1-5, and tumors with the most favorable features (Gleason score 6) are referred to as Grade Group 1. Recently, the distinct risk of biochemical recurrence (BCR) based on each Grade Group has been confirmed in a large multi-institutional study [ [7] . This recommendation was based on poor interobserver reproducibility and a lack of correlation with radical prostatectomy grade where a diagnosis of Gleason score 2-4 may misguide clinicians and patients into believing that the patient had an indolent tumor. In 2005, it was agreed that Gleason scores 2-4 should no longer be assigned to tumors detected on needle biopsy and Gleason scores 2 þ 2 ¼ 4 and 2 þ 3 ¼ 5 may only rarely be diagnosed on transurethral resection or prostatectomy specimens, commonly in association with higher grade dominant tumors. Consequently, the lowest score currently assigned to a prostate tumor on needle biopsy is 3 þ 3 ¼ 6, despite the fact that the Gleason grading system ranges from 2 to 10. This has created significant confusion among patients and clinicians.
Changes in the morphologic criteria for inclusion in Gleason pattern 3 and 4 resulting from both the 2005 and 2014 consensus conferences have resulted in shrinkage of Gleason pattern 3 and expansion of Gleason pattern 4. Only discrete well formed glands, including branched glands, are currently included in the modified Gleason pattern 3; all cribriform glands lacking basal cells, regardless of size and morphology, are graded as Gleason pattern 4 in the current modified grading system; similarly fused, poorly formed and glomeruloid glands are considered part of Gleason pattern 4. In Gleason's original grading scheme, Gleason pattern 3 included some types of cribriform glands as well as poorly formed glands. These changes have resulted in a shift in grading, with an increase in the percentage of Gleason score 7 relative to Gleason score 6 cancers in any given patient population; moreover, as certain architectural patterns previously included in Gleason pattern 3 are now considered pattern 4, prostate cancers graded as Gleason score 3 þ 3 ¼ 6 by the ISUP modified grading system have a better prognosis when compared to Gleason score 6 tumors based on the original Gleason score [8] . The concordance between biopsy and subsequent prostatectomy grading has also improved [9, 10] .
Another significant change with major implications adopted in 2005 is that in the setting of high-grade cancer on needle biopsy, the lower grade pattern should not be included in the Gleason score if it represents less than 5% of the tumor area. Similarly, in the setting of three distinct patterns (pattern 3, 4, and 5) on needle biopsy, the most prevalent pattern should be added to the highest one, instead of to the second most common pattern [1] . The presence of tertiary pattern 5 on radical prostatectomy specimens has been a controversial topic for some time; the 2005 ISUP recommendation was to include pattern 5 in the final Gleason score if it represented more than 5% of the tumor area, or to report it as a tertiary pattern if it occupied less than 5% of the tumor. The 2014 conference specified that tertiary patterns should only be recorded for radical prostatectomy specimens with either 3 þ 4 ¼ 7 or 4 þ 3 ¼ 7 with tertiary pattern 5.
The 2005 consensus conference defined grading rules for new morphologic patterns of prostate cancer (pseudohyperplastic, foamy glands, and atrophic) and the 2014 consensus conference agreed that mucinous carcinomas should be graded based on their architectural pattern, after mentally subtracting the extravasated mucin. At the 2014 consensus conference, it was agreed to report the presence of intraductal carcinoma, but not to grade it [2 && ].
KEY POINTS
Prostate cancer Gleason grading has been recently updated at the 2014 ISUP consensus conference.
A new grading system that translates Gleason grades into five risk categories (Grade Groups 1-5) has been endorsed by the ISUP and the WHO. The novel grading system has been validated in a large multi-institutional study and in a nationwide populationbased cohort of men with prostate cancer treated by radical prostatectomy or radiation therapy, and in a series of men with long-term follow-up, treated conservatively.
Grade Group 1 (Gleason score 6) tumors have an excellent prognosis.
Grade Groups 2 (Gleason score 3 þ 4 ¼ 7) and Grade Group 3 (Gleason score 4 þ 3 ¼ 7) tumors have significantly different prognosis.
At the 2014 consensus conference, it was recommended to report the percentage of pattern 4 in Gleason score 7 tumors, particularly in Gleason score 3 þ 4 ¼ 7 cancers, as patients with a minor component (<5%) of pattern 4 may be deemed eligible for active surveillance [11] .
GRADE GROUPS
Despite current changes, the modified Gleason grading is clinically a suboptimal system. Patients diagnosed with Gleason score 6 prostate cancer erroneously assume that their tumor is of intermediate risk, despite the fact that Gleason score 6 is the lowest grade used on prostate needle biopsy. Different classification systems in the literature have combined tumors with different Gleason scores for treatment and prognostic purposes [12] . The D'Amico classification, widely used in clinical practice, divides prostate cancer into 'low grade' (Gleason score 6), 'intermediate grade' (Gleason score 7), and 'high grade' (Gleason score 8-10) tumors [13] . The intermediate grade category includes Gleason score 3 þ 4 ¼ 7 and 4 þ 3 ¼ 7 prostatic adenocarcinomas, despite numerous studies have demonstrated worse outcome for patients with Gleason score 7 with primary pattern 4 versus 3 [14] [15] [16] . Similarly, Gleason score 9-10 tumors have a worse prognosis than Gleason score 4 þ 4 ¼ 8 tumors [3] .
In 2013, a new grading system for prostate cancer was proposed to address some of the inconsistencies and limitations of the modified Gleason system. The new grading system, based on data from 7869 radical prostatectomies collected at the Johns Hopkins Hospital, suggested five distinct Grade Groups, from 1 to 5 [3]. Grade Group 1 includes tumors composed only of individual discrete well formed glands (Gleason score 6); Grade Group 2 includes tumors composed predominantly of well formed glands with a lesser component of poorly formed/fused/cribriform glands (Gleason score 3 þ 4 ¼ 7); Grade Group 3 includes tumors with predominantly poorly formed/fused/cribriform glands with a lesser component of well formed glands (Gleason score 4 þ 3 ¼ 7); Grade Group 4 includes tumors composed only of poorly formed/fused/cribriform glands or tumors with well formed glands and lesser component lacking glands, or tumors predominantly lacking glands with a lesser component of well formed glands (Gleason score 4 þ 4 ¼ 8; 3 þ 5 ¼ 8; 5 þ 3 ¼ 8), and Grade Group 5 includes tumors lacking gland formation (or with necrosis) with or without poorly formed/fused/ cribriform glands (Gleason score 9/10). Tertiary pattern 5 on 3 þ 4 ¼ 7 and 4 þ 3 ¼ 7 tumors at radical prostatectomy would be recorded as Grade Group 2 and 3, respectively, with a minor higher grade pattern or possibly in the future as Grade Groups 2 þ or 3 þ [17] .
This new prostate grading system was adopted with a broad consensus (90%) at the 2014 ISUP consensus conference [2 && ] and has been accepted by the World Health Organization (WHO) for the 2016 edition of WHO classification of Tumours of the Urinary System and Male Genital Organs [18] . The editors of the major uro-oncology journals are now recommending investigators to use the new system in the reporting of prostate cancer in their publications [19] [20] [21] . The updated protocols from the College of American Pathologists and the 8th edition of the American Joint Committee on Cancer staging manual will also incorporate the new prostate grading system. At the present time, it has been recommended to report the new grading system in concomitance with the Gleason grading system.
GRADE GROUPS PROGNOSTIC VALUE IN RADICAL PROSTATECTOMY AND RADIATION THERAPY COHORTS AND IMPLICATIONS FOR THERAPEUTIC OPTIONS
In the original paper, Pierorazio and colleagues showed that Grade Groups on radical prostatectomy predicted BCR at a median follow-up of 2 years. The 5-year BCR-free survival for Grade Groups 1 to 5 at radical prostatectomy was 97, 88, 70, 64, and 34%, respectively [3]. Subsequently, the novel grading system was validated in a multi-institutional study, including 20 845 consecutive men treated by radical prostatectomy at five large academic centers and 5501 men treated by radiation therapy at two centers. In the surgery cohort, the 5-year BCR-free survival for Grade Groups 1 to 5 based on prostatectomy grade was 96, 88, 63, 48, and 26%, respectively [4 && ] (Fig. 1 ). These differences between 3 þ 4 and 4 þ 3 were attenuated in the radiotherapy cohort as a whole because of increased adjuvant or neoadjuvant hormones for patients with high-grade disease, but were clearly seen in patients undergoing radiotherapy only.
Loeb and colleagues [5 & ] have recently evaluated the performance of the new Grade Groups in 5880 men with prostate cancer (4325 treated by radical prostatectomy and 1555 by radiation therapy) from a nationwide population-based cohort and have reported that among men treated with surgery, the 4-year BCR-free survival rates based on prostatectomy Grade Groups 1-5 were 92, 85, 73, 63, and 51%, respectively.
All the above mentioned studies confirm that Grade Group 1 (Gleason score 6) tumors have an excellent prognosis. Similarly, Ross et al. [22] analyzed more than 14 000 entirely submitted radical prostatectomies with Gleason score 3 þ 3 ¼ 6 and reported no evidence of metastatic potential. The new Grade Group system reflects the lowest possible grade for Gleason score 6 tumors (Grade Group 1) and helps the patient understand the high probability of being cured when diagnosed with such tumors. Grade Group 2 of 5 reflects the good prognosis of Gleason score 3 þ 4 ¼ 7 patients and distinguishes them from Grade Group 3 of 5 (Gleason score 4 þ 3 ¼ 7), who have a significantly worse prognosis [4 && ,5 & ,23]. Similarly, the new grading system discriminates between Grade Group 4 (Gleason score 4 þ 4 ¼ 8) and 5 (Gleason score 9-10) tumors, based on their significantly worse prostate cancer-related outcomes [3,4 && ,24]. Large differences in recurrence rates were seen in the multi-institutional validation study between both Gleason 3 þ 4 versus 4 þ 3 and Gleason score 8 versus 9-10 in the radical prostatectomy cohort. The hazard ratios relative to Gleason score 6 were 1.9, 5.1, 8.0, and 11.7 for Gleason scores 3 þ 4, 4 þ 3, 8, and 9-10, respectively [4 && ]. Patients with Gleason score 9-10 tumors may warrant more aggressive treatment modalities.
GRADE GROUPS PROGNOSTIC VALUE ON NEEDLE BIOPSY AND IMPLICATIONS FOR ACTIVE SURVEILLANCE
Similarly to radical prostatectomy grade, the 5-year BCR-free survival for Grade Groups 1 to 5 on biopsy was 95, 83, 65, 63, and 34%, respectively in the Johns Hopkins series [3] . The 5 Grade Groups were also predictive for biopsy grade followed by radical prostatectomy in the multi-institutional study [4 && ]; the hazard ratios relative to biopsy Gleason score 6 were 2.5, 5.7, 9.1, and 13.8 for Gleason scores 3 þ 4, 4 þ 3, 8, and 9-10, respectively [4 && ]. Loeb and colleagues reported a statistically significant relationship between biopsy Grade Groups and presence of one or more adverse features at radical prostatectomy. After adjusting for preoperative serum prostate-specific antigen and clinical stage, biopsy Grade Groups were significant independent predictors of BCR and prostate cancer death after radical prostatectomy and radiation therapy. Among men treated with surgery, the 4-year BCR-free survival rates were 89, 82, 74, 77, and 49% for biopsy Grade Groups 1-5, respectively; for men treated by radiation therapy, the BCR-free survival rates were 95, 91, 85, 78, and 70%, respectively [5 & ]. More recently Berney et al. [25] have shown that the new prostate cancer Grade Groups correlate with prostate cancer death in a series of men with long-term follow-up, treated conservatively.
As the Grade Groups system starts from 1 it is easy and intuitive to interpret a Grade Group 1 tumor as a low-risk tumor and the lowest grade possible on a scale from 1 to 5, in contrast of Gleason score 6 out of 10. The distinction of low-grade tumors is particularly important for patients considering active surveillance to reassure them that Grade Group 1 tumors have a good prognosis and can be addressed by close monitoring instead of definitive treatment. The new Grade Groups system distinguishes patients with Gleason score 7 into two distinct categories, Grade Groups 2 (Gleason score 3 þ 4 ¼ 7) and Grade Group 3 (Gleason score 4 þ 3 ¼ 7) with significantly different prognosis [4 && ,5 & ,23]. As some patients with Gleason score 3 þ 4 prostate cancer with a small percentage of pattern 4 and low tumor volume on biopsy are considered eligible for active surveillance [26, 27] , it is important to distinguish Gleason score 3 þ 4 ¼ 7 from Gleason score 4 þ 3 ¼ 7 tumors and to report the percentage of pattern 4 present on needle biopsy, as recommended at the 2014 consensus conference [2 && ].
GENOMIC CORRELATION OF GRADE GROUPS
Rubin et al.
[6 & ] demonstrated molecular support for the newly proposed Grade Groups system in a cohort of 426 clinically localized prostate cancers treated by radical prostatectomy. They observed a significant increase in genomic amplifications and deletions and nonsynonymous point mutations Years since surgery Prob. of recurrence-free progression 7 8 9 1 0 GG5 GG4 GG3 GG2 GG1 FIGURE 1. Risk of biochemical recurrence stratified by radical prostatectomy Grade Groups 1-5. Reproduced with permission from European Urology. GG, Grade Groups.
